7 unchanged sentences
As a result of that assessment, management concluded that our internal control over financial reporting was effective as of October 31, 2021 based on criteria in Internal Control - Integrated Framework (2013) issued by the COSO.
+Added: SEC staff guidance discusses the exclusion of an acquired business’s internal controls from management’s annual assessment of the internal controls over financial reporting when it is not possible to conduct assessments for the acquired business in the period between the acquisition date and the date of management’s assessment.
+Added: We completed the acquisition of Resolution Bioscience on April 15, 2021.
+Added: Management excluded Resolution Bioscience from its assessment of the effectiveness of our internal control over financial reporting as of October 31, 2021.
+Added: Resolution Bioscience constituted less than 1 percent of our total revenue for the period ending October 31, 2021 and less than 1 percent of total assets, excluding acquired goodwill and other intangible assets, as of October 31, 2021.
The effectiveness of our internal control over financial reporting as of October 31, 2021 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which appears in Item 8 of this Annual Report on Form 10-K.
6 unchanged sentences
That portion of the Proxy Statement is incorporated by reference into this report.
−Removed: Information regarding our executive officers appears in Item 1 of this report under “Executive Officers of the Registrant.” Information regarding our Audit and Finance Committee and our Audit and Finance Committee's financial expert appears under “Audit and Finance Committee Report” and “Corporate Governance” in our Proxy Statement.
+Added: Information regarding our executive officers appears in Item 1 of this report under “Executive Officers of the Registrant.” Information regarding our Audit and Finance Committee and our Audit and Finance
+Added: Committee's financial expert appears under “Audit and Finance Committee Report” and “Corporate Governance” in our Proxy Statement.
That portion of the Proxy Statement is incorporated by reference into this report.
36 unchanged sentences
The 2018 Plan provides for awards of stock-based incentive compensation to our employees (including officers), directors and consultants.
−Removed: The 2018 Plan provides for the grant of awards in the form of stock options, stock appreciation rights, restricted stock, restricted stock units, performance shares and performance units with performance-based conditions to vesting or exercisability, and cash awards.
+Added: The 2018 Plan provides for the grant of awards in the form of stock options, stock appreciation rights,
+Added: restricted stock, restricted stock units, performance shares and performance units with performance-based conditions to vesting or exercisability, and cash awards.
The 2018 Plan has a term of ten years.
47 unchanged sentences
S-3ASR 10/24/2007 4.01
−Removed: 4.3 Sixth Supplemental Indenture, dated as of September 13, 2012, between the Company and U.S.
−Removed: Bank National Association
−Removed: 8-K 9/13/2012 4.01
4.3 Seventh Supplemental Indenture, dated as of June 21, 2013, between the Company and U.S.
13 unchanged sentences
8-K 6/4/2020 4.1
+Added: 4.8 Indenture dated as of March 12, 2021, between the Company and Citibank, N.A.
+Added: 8-K 3/12/2021 4.1
+Added: 4.9 First Supplemental Indenture, dated as of March 12, 2021, between the Company and Citibank, N.A.
+Added: and Form of Global Note for the Company’s 2.300% Senior Notes due 2031.
+Added: 8-K 3/12/2021 4.2
4.10 Description of Securities
12 unchanged sentences
10-Q 6/1/2020 10.1
+Added: Incorporation by Reference
+Added: Number Description Form Date Exhibit
10.5 Agilent Technologies, Inc.
4 unchanged sentences
10‑K 12/20/2010 10.17
−Removed: Incorporation by Reference
−Removed: Number Description Form Date Exhibit
10.7 Form of Stock Option Award Agreement under the 2009 Stock Plan for U.S.
40 unchanged sentences
DEF14A 2/6/2015 Annex A
+Added: Incorporation by Reference
+Added: Number Description Form Date Exhibit
10.24 Form of Amended and Restated Indemnification Agreement between Agilent Technologies, Inc.
1 unchanged sentence
8-K 4/10/2008 10.1
−Removed: Incorporation by Reference
−Removed: Number Description Form Date Exhibit
10.25 Form of Tier I Change of Control Severance Agreement between Agilent Technologies, Inc.
5 unchanged sentences
10.27 Form of Tier II Change of Control Severance Agreement between Agilent Technologies, Inc.
−Removed: and Section 16 Officers (other than the Company’s Chief Executive Offi c er)*
+Added: and Section 16 Officers (other than the Company’s Chief Executive Officer)*
10-K 12/22/2014 10.37
31 unchanged sentences
8-K 4/20/2020 10.1
+Added: 10.39 Incremental Assumption Agreement dated as of April 21, 2021, by and among the Company, the Lenders party thereto and BNP Paribas, as Administrative Agent
+Added: 8-K 4/22/2021 10.1
+Added: Incorporation by Reference
+Added: Number Description Form Date Exhibit
10.40 Letter of Terms and Conditions International Long Term Assignment, by and among Jacob Thaysen and the Company*
2 unchanged sentences
10-K 12/21/2015 10.70
−Removed: Incorporation by Reference
−Removed: Number Description Form Date Exhibit
10.42 Letter of Terms and Conditions of U.S.
28 unchanged sentences
* Indicates management contract or compensatory plan, contract or arrangement.
+Added: Form 10-K Summary
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
21 unchanged sentences
BISHOP Director December 17, 2021
+Added: BRAWLEY, M.D.
+Added: Director December 17, 2021
+Added: Brawley, M.D.
CLARK Director December 17, 2021
+Added: MIKAEL DOLSTEN, M.D., PH.D.
+Added: Director December 17, 2021
+Added: Mikael Dolsten, M.D., PH.D.
/s/ HEIDI KUNZ Director December 17, 2021
9 unchanged sentences
WILSON Director December 17, 2021
−Removed: /s/ TADATAKA YAMADA, M.D.
−Removed: Director December 17, 2020
−Removed: Tadataka Yamada, M.D.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.